Market-Moving News for March 27th
$DRCT
$IBIO
$NVCR
Advertising
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $DRCT alert in real time by email
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/21/2025 | $5.00 | Outperform | Oppenheimer | |
| 10/17/2025 | $2.00 | Outperform | Leerink Partners | |
| 7/25/2025 | $14.50 | Overweight → Equal Weight | Wells Fargo | |
| 7/8/2025 | $30.00 | Buy | Ladenburg Thalmann | |
| 12/2/2024 | $18.00 → $30.00 | In-line → Outperform | Evercore ISI | |
| 10/16/2024 | $24.00 → $30.00 | Neutral → Buy | H.C. Wainwright | |
| 5/28/2024 | $5.00 | Buy | Chardan Capital Markets | |
| 3/27/2024 | Outperform → Market Perform | Noble Capital Markets |
Oppenheimer initiated coverage of iBio with a rating of Outperform and set a new price target of $5.00
Leerink Partners initiated coverage of iBio with a rating of Outperform and set a new price target of $2.00
Wells Fargo downgraded NovoCure from Overweight to Equal Weight and set a new price target of $14.50
S-8 - Direct Digital Holdings, Inc. (0001880613) (Filer)
8-K - NovoCure Ltd (0001645113) (Filer)
424B3 - Direct Digital Holdings, Inc. (0001880613) (Filer)
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway Progressed Pipeline with New Preclinical Data and Scientific Presentations at Leading Industry Conferences SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today reported financial results for the second quarter ended Dec. 31, 2025, and provided a corporate update on its progress. "We have significantly advanced our preclinical pipeline programs - IBIO-610, our activin E antibody, and IBIO-600, our myostatin antibody - towards the start of human clinical trials by initiating CMC devel
New webinar breaks down one of the industry's first tested geo frameworks for AI search AUSTIN, Texas and PIGEON FORGE, Tenn., Feb. 10, 2026 /PRNewswire/ -- Orange 142, LLC ("Orange 142"), a division of Direct Digital Holdings (NASDAQ:DRCT) and a leading digital marketing agency for mid-market brands and agencies, in partnership with the 4As and the Pigeon Forge Department of Tourism, today announced an upcoming webinar on how a leading travel destination adapted its digital strategy to remain visible as consumer discovery shifts toward AI-driven search. Titled How to Get Your Brand Recommended by AI: A Pigeon Forge Case Study, the webinar will outline a practical, tested approach to Generat
Appointment builds on Orange 142's work helping destination organizations drive visitation, revenue, and community impact AUSTIN, Texas, Feb. 5, 2026 /PRNewswire/ -- Orange 142, LLC ("Orange 142"), a leading digital marketing agency and a division of Direct Digital Holdings (NASDAQ:DRCT), today announced that Cassandra Razzi, Senior Manager of Business Development, has been named to the 2026 Social Impact Committee of Destinations International (DI), the world's largest association for destination organizations and tourism professionals. The appointment reflects Orange 142's ongoing work with destination marketing organizations (DMOs) to expand reach, drive revenue, and support responsible
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - iBio, Inc. (0001420720) (Issuer)
4 - iBio, Inc. (0001420720) (Issuer)
4 - iBio, Inc. (0001420720) (Issuer)
4 - iBio, Inc. (0001420720) (Issuer)
Novocure (NASDAQ:NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. "During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer therapy to patients to extend their survivals. Frank has been instrumental in creating Novocure's culture and guiding the organization at critical points, including preparing the company for its first commercial launch and establishing the business functions that continue to
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we
Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PST on Wednesday, January 14, 2026 Novocure (NASDAQ:NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on the exci
HOUSTON, Jan. 8, 2026 /PRNewswire/ -- Direct Digital Holdings, Inc. (NASDAQ:DRCT) ("Direct Digital Holdings" or the "Company"), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC ("Colossus SSP") and Orange 142, LLC ("Orange 142"), today announced a 55-to-1 reverse stock split of all classes of its common stock. The Company expects the Class A common stock to begin trading on a split-adjusted basis on The Nasdaq Stock Market as of the commencement of trading on January 12, 2026. The reverse stock split is intended to allow the Company to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse stock
HOUSTON, Nov. 13, 2025 /PRNewswire/ -- Direct Digital Holdings, Inc. (NASDAQ:DRCT) ("Direct Digital Holdings" or the "Company"), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC ("Colossus SSP") and Orange 142, LLC ("Orange 142"), today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that it has regained compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. Additionally,
SC 13D/A - Direct Digital Holdings, Inc. (0001880613) (Subject)
SC 13G - iBio, Inc. (0001420720) (Subject)
SC 13G/A - iBio, Inc. (0001420720) (Subject)